Key Points
- Corti, the Copenhagen-based clinical AI company, has launched a no-equity Startup Acceleration Program for healthcare and life sciences startups worldwide.
- The programme offers access to Corti’s Symphony model stack, including agents, medical coding, speech-to-text and text generation, plus up to $5,000 in credits.
- Corti said its Symphony model has outscored OpenAI on HealthBench Professional, its healthcare benchmark.
- The initiative is positioned as support for founders facing heavy compliance and deployment costs in healthcare AI, especially in Europe.
- Corti said it will provide help on EU AI Act, MDR and data-residency issues, alongside roadmap guidance and founder webinars.
- Applications are open on a rolling basis, with a one-week turnaround, and the programme carries no pitch process and no equity requirement.
- The launch comes as OpenAI has expanded clinical AI access in the United States, while OpenEvidence has withdrawn from the UK and European markets citing regulatory uncertainty.
- Corti said the EU MDR certification burden can cost founders between €200,000 and €600,000 per device and can take 12 to 18 months.
- The programme is open to pre-seed through Series B companies building in healthcare, clinical workflows or adjacent life sciences.
What did Corti announce?
As reported by PR Newswire, Corti said it has launched the Startup Acceleration Program, a no-equity initiative designed to help healthcare AI builders ship and scale at a time when regulatory pressure is rising across major markets.
The company described itself as a frontier lab for clinical-grade AI and said the programme is intended to bridge the gap between benchmark performance and actual deployment in healthcare settings. Corti said the initiative is grant-funded and gives founders access to the same clinical-grade models that support AI systems used in highly regulated environments in Europe and the United States.
Why is Europe central to this story?
As reported by The Next Web, Europe is the toughest proving ground for clinical AI because compliance demands are increasing while the cost of entering the market remains high.
Corti said this is especially relevant because the EU AI Act and the Medical Device Regulation create a difficult environment for startups building medical AI tools. The company said EU MDR certification alone can cost between €200,000 and €600,000 per device and can take 12 to 18 months, a burden it believes can deter younger companies from entering the market.
How does the accelerator work?
According to tech.eu, the programme offers up to $5,000 in credits across the Symphony stack, which includes agents, medical coding, speech-to-text and text generation.
Corti said participants will also receive direct support from its clinical and regulatory team on EU AI Act, MDR and data-residency issues. It added that founders will have dedicated time with its AI experts to scope product roadmaps and design systems before code is written. The company also said the programme includes founder-led webinars and invitations to Corti events in New York, Copenhagen, London and Berlin.
What did Corti say about OpenAI?
Corti said its Symphony model has outscored OpenAI on HealthBench Professional, the company’s healthcare benchmark.
The PR Newswire release framed this as evidence that vertical, clinical-grade AI can outperform general-purpose systems in healthcare-specific tasks. The company’s message appeared to contrast the progress of horizontal AI firms with the more specialised demands of regulated medical workflows.
What role did OpenEvidence play?
As reported by PR Newswire and tech.eu, OpenEvidence withdrew from the UK and European markets one week after OpenAI rolled out free clinical AI to verified American physicians.
The reports said OpenEvidence is a clinical AI platform used daily by around 40 per cent of US physicians and valued at $12 billion. The company said it exited Europe because of regulatory uncertainty linked to the EU AI Act. Corti used that retreat to underline its argument that Europe is becoming harder for general-purpose or lightly adapted AI products to serve.
What does Corti want startups to build?
According to the reports, the accelerator is open to pre-seed through Series B companies building in healthcare, clinical workflows or adjacent life sciences.
Corti said there is no pitch process, no committee and no equity component. Applications are open immediately and will be reviewed on a rolling basis, with a one-week turnaround. The company’s pitch is that founders should be able to focus on product and regulation without taking on the entire compliance burden alone.
What is the wider market context?
The story sits at the intersection of two trends: OpenAI’s move into clinical AI and the retreat of some companies from Europe’s regulated market.
Corti argued that the “structural difficulty” of entering Europe is pushing out horizontal players and the vertical products built on them. At the same time, it wants to position itself as infrastructure for the next generation of healthcare AI companies rather than as a competitor only in finished applications. That strategy also reflects a broader industry split between general-purpose AI and sector-specific tools designed for regulated use.
What does this mean for healthcare AI founders?
For founders, Corti’s move signals that access to clinical AI infrastructure and regulatory support is becoming a competitive advantage.
Startups entering healthcare AI now face a market where technical performance alone is not enough, because legal, compliance and deployment requirements can block market entry. Corti is betting that offering credits, expert support and a no-equity structure will make it more attractive for early-stage teams to build in the space. Its message is that the next wave of healthcare startups will need both strong models and a clear path through regulation.